This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/russia/510297-vaccine-putin-astrazeneca-deal/
The article has changed 4 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| Creators of Russia’s Sputnik V Covid-19 vaccine sign Putin-backed deal with UK pharma giant AstraZeneca in bid to boost efficacy | Creators of Russia’s Sputnik V Covid-19 vaccine sign Putin-backed deal with UK pharma giant AstraZeneca in bid to boost efficacy |
| (32 minutes later) | |
| Scientists at Moscow’s Gamaleya Institute signed a memorandum of understanding with British firm AstraZeneca on Monday, signaling the start of cooperation between the two in the fight against the coronavirus. | Scientists at Moscow’s Gamaleya Institute signed a memorandum of understanding with British firm AstraZeneca on Monday, signaling the start of cooperation between the two in the fight against the coronavirus. |
| The partnership, originally proposed by the Russian team over Twitter and announced at the start of December, will see the pharma giant trial its Covid-19 vaccine candidate in combination with the Russian-made Sputnik-V jab.Russian President Vladimir Putin spoke with drug company bosses via video link on Monday morning, congratulating them on reaching the agreement. He said that “this attitude towards partnership today can serve as a good, convincing example of combining scientific forces, technology, investment for a common goal – to protect the lives, health and safety of millions of people on the planet as a whole.”Clinical trials will now determine whether AstraZeneca’s formula can produce better results by incorporating elements of Sputnik V. The Russian offering, its creators say, has proven effective in 95 percent of participants given two shots as part of clinical trials. In November, AstraZeneca said its own vaccine had shown a 70 percent efficacy average. It is hoped that trials using the two different formulas together will improve that figure. | |
| DETAILS TO FOLLOW | DETAILS TO FOLLOW |